Cognitive impairment associated to leukoaraiosis: Its pathophysiology, clinical manifestations and treatment;Deterioro cognitivo asociado a la leucoaraiosis: Fisiopatología, manifestaciones clínicas y tratamiento

Revista de Neurologia

Volumn 47, Issue 10, 2008, Pages 536-544

  Jimenez I ^a   Agulla, J ^a   Pouso, M ^a   Sabucedo, M ^a   Rodriguez Yanez M ^a   Sobrino, T ^a   Brea, D ^a   Blanco, M ^a   Leira, R ^a   Castillo, José ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Leukoaraiosis; Molecular markers; Vascular dementia; White matter disease

Indexed keywords

CHOLINESTERASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BRAIN ARTERY; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; HUMAN; LEUKOARAIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; WHITE MATTER;

EID: 57049159848     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4710.2008386     Document Type: Review

References (94)

1. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol 1987; 44: 21-3.
2. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28: 652-9.
3. Van Gijn J. Leukoaraiosis and vascular dementia. Neurology 1998; 51 (Suppl 3): S3-8.
4. Basile AM, Pantoni L, Pracucci G, Asplund K, Chabriat H, Erkinjuntti T, et al. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (leukoaraiosis and disability in the elderly) study. Cerebrovasc Dis 2006; 21: 315-22.
5. Kohara K, Zhao B, Jiang Y, Takata Y, Fukuoka T, Igase M, et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999; 83: 367-70.
6. Patankar T, Widjaja E, Chant H, McCollum C, Baldwin R, Jeffries S, et al. Relationship of deep white matter hyperintensities and cerebral blood flow in severe carotid artery stenosis. Eur J Neurol 2006; 13: 10-6.
7. Wiszniewska M, Devuyst G, Bogousslavsky J, Ghika J, Van Melle G. What is the significance of leukoaraiosis in patients with acute ischemic stroke? Arch Neurol 2000; 57: 967-73.
8. Kelley RE. Ischemic demyelination. Neurol Res 2006; 28: 334-40.
9. Libon DJ, Bogdanoff B, Leopold N, Hurka R, Bonavita J, Skalina S, et al. Neuropsychological profiles associated with subcortical white matter alterations and Parkinson's disease: implications for the diagnosis of dementia. Arch Clin Neuropsychol 2001; 16: 19-32.
10. Mantyla R, Aronen HJ, Salonen O, Pohjasvaara T, Korpelainen M, Peltonen T, et al. Magnetic resonance imaging white matter hyperintensities and mechanism of ischemic stroke. Stroke 1999; 30: 2053-8.
11. Van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44 :625-30.
12. Roman GC. Cerebral microcirculation: anatomy and function. In Roman GC, ed. Managing vascular dementia. London: Science Press; 2003. p. 18-24.
13. Turner ST, Fornage M. Genetics of leukoaraiosis. J Stroke Cerebrovasc Dis 2002; 11: 241-51.
14. Fornage M, Mosley TH, Jack CR, De Andrade M, Kardia SL, Boerwinkle E, et al. Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. Hum Genet 2007; 120: 671-80.
15. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-72.
16. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, et al. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab 2001; 21: 828-34.
17. Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, Takahashi R, et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 2006; 37: 2816-23.
18. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126: 424-32.
19. Szolnoki Z. Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromolecular Med 2007; 9: 21-34.
20. Sánchez-Pérez RM, Hernández-Lorido R, Castaño-Pérez MD, Díaz-Marín C, Carneado-Ruiz J, Moltó-Jordà J. Estudio de los parámetros hemodinámicos en pacientes con leucoaraiosis mediante Doppler transcraneal. Rev Neurol 2003; 37: 301-11.
21. Burkhart KK, Beard DC, Lehman RA, Billingsley ML. Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation. Exp Neurol 1998; 154: 464-72.
22. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998; 143: 777-94.
23. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 806-12.
24. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003; 74: 70-6.
25. Szolnoki Z. Chemical events behind leukoaraiosis: medicinal chemistry offers new insight into a specific microcirculation disturbance in the brain (a chemical approach to a frequent cerebral phenotype). Curr Med Chem 2007; 14: 1027-36.
26. Krum JM, Mani N, Rosenstein JM. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 2002; 110: 589-604.
27. Hai J, Li ST, Lin Q, Pan QG, Gao F, Ding MX. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery 2003; 53: 963-72.
28. Lazarovici P, Marcinkiewicz C, Lelkes PI. Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 2006; 12: 2609-22.
29. Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem 2006; 13: 1655-65.
30. Kwa VI, Van der Sande JJ, Stam J, Tijmes N, Vrooland JL. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002; 59: 1536-40.
31. Poirier J, Grey F, Escourolle R. Manual of basic neuropathology. Philadelphia: W.B. Saunders; 1999.
32. Farkas E, Donka G, De Vos RA, Mihaly A, Bari F, Luiten PG. Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol (Berl) 2004; 108: 57-64.
33. Ohta H, Nishikawa H, Kimura H, Anayama H, Miyamoto M. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience 1997; 79: 1039-50.
34. Takizawa S, Fukuyama N, Hirabayashi H, Kohara S, Kazahari S, Shinohara Y, et al. Quercetin, a natural flavonoid, attenuates vacuolar formation in the optic tract in rat chronic cerebral hypoperfusion model. Brain Res 2003; 980: 156-60.
35. Wakita H, Tomimoto H, Akiguchi I, Matsuo A, Lin JX, Ihara M, et al. Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res 2002; 924: 63-70.
36. Cho KO, La HO, Cho YJ, Sung KW, Kim SY. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J Neurosci Res 2006; 83: 285-91.
37. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, et al. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 2006; 1082: 182-91.
38. Tomimoto H, Ihara M, Wakita H, Ohtani R, Lin JX, Akiguchi I, et al. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol 2003; 106: 527-34.
39. Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M, et al. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol 2002; 28: 238-51.
40. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 1995; 45: 883-8.
41. Thomas AJ, Perry R, Barber R, Kalaria RN, O'Brien JT. Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann N Y Acad Sci 2002; 977: 333-9.
42. Tomimoto H, Akiguchi I, Wakita H, Kimura J. White matter lesions after occlusion of the bilateral carotid arteries in the rat -temporal profile of cerebral blood flow (CBF), oligodendroglia and myelin. No To Shinkei 1997; 49: 639-44.
43. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. Long-term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003; 30: 266-72.
44. Marosi M, Rakos G, Robotka H, Nemeth H, Sas K, Kis Z, et al. Hippocampal (ca1) activities in Wistar rats from different vendors. Fundamental differences in acute ischemia. J Neurosci Methods 2006; 156: 231-5.
45. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007; 54: 162-80.
46. Choy M, Ganesan V, Thomas DL, Thornton JS, Proctor E, King MD, et al. The chronic vascular and haemodynamic response after permanent bilateral common carotid occlusion in newborn and adult rats. J Cereb Blood Flow Metab 2006; 26: 1066-75.
47. De la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci 2000; 924: 136-52.
48. De Bortoli VC, Zangrossi H Jr, De Aguiar-Correa FM, Almeida SS, De Oliveira AM. Inhibitory avoidance memory retention in the elevated Tmaze is impaired after perivascular manipulation of the common carotid arteries. Life Sci 2005; 76: 2103-14.
49. Sarti C, Pantoni L, Bartolini L, Inzitari D. Persistent impairment of gait performances and working memory after bilateral common carotid artery occlusion in the adult Wistar rat. Behav Brain Res 2002; 136: 13-20.
50. Zubilewicz T, Wronski J, Bourriez A, Terlecki P, Guinault AM, Muscatelli-Groux B, et al. Injury in vascular surgery -the intimal hyperplastic response. Med Sci Monit 2001; 7: 316-24.
51. Tanaka Y, Imai H, Konno K, Miyagishima T, Kubota C, Puentes S, et al. Experimental model of lacunar infarction in the gyrencephalic brain of the miniature pig: neurological assessment and histological, immunohistochemical, and physiological evaluation of dynamic corticospinal tract deformation. Stroke 2008; 39: 205-12.
52. Peng Y, Xu S, Chen G, Wang L, Feng Y, Wang X. L-3-n-butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharmacol Exp Ther 2007; 321: 902-10.
53. Kuang X, Du JR, Liu YX, Zhang GY, Peng HY. Postischemic administration of z-ligustilide ameliorates cognitive dysfunction and brain damage induced by permanent forebrain ischemia in rats. Pharmacol Biochem Behav 2008; 88: 213-21.
54. Ohtani R, Tomimoto H, Wakita H, Kitaguchi H, Nakaji K, Takahashi R. Expression of s100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res 2007; 1135: 195-200.
55. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006; 37: 1539-45.
56. Fan LW, Lin S, Pang Y, Rhodes PG, Cai Z. Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur J Neurosci 2006; 24: 341-50.
57. Vataja R, Pohjasvaara T, Mantyla R, Ylikoski R, Leppavuori A, Leskela M, et al. MRI correlates of executive dysfunction in patients with ischaemic stroke. Eur J Neurol 2003; 10: 625-31.
58. De Groot JC, De Leeuw FE, Oudkerk M, Van Gijn J, Hofman A, Jolles J, et al. Cerebral white matter lesions and cognitive function: the Rotterdam scan study. Ann Neurol 2000; 47: 145-51.
59. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000; 14: 224-32.
60. Jokinen H, Kalska H, Mantyla R, Ylikoski R, Hietanen M, Pohjasvaara T, et al. White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry 2005; 76: 1229-33.
61. Burton EJ, Kenny RA, O'Brien J, Stephens S, Bradbury M, Rowan E, et al. White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. Stroke 2004; 35: 1270-5.
62. Bartres-Faz D, Clemente IC, Junqué C. Cambios en la sustancia blanca y rendimiento cognitivo en el envejecimiento. Rev Neurol 2001; 33: 347-53.
63. O'Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 2004; 75: 441-7.
64. Tullberg M, Fletcher E, DeCarli C, Mungas D, Reed BR, Harvey DJ, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004; 63: 246-53.
65. Wen HM, Mok VC, Fan YH, Lam WW, Tang WK, Wong A, et al. Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 2004; 35: 1826-30.
66. Blanco-Menéndez R, Aguado-Balsas AM, Blanco E, Lobo-Rodríguez B, Vera-De la Puente E. El síndrome de CADASIL: un modelo de desconexión córtico subcortical. Rev Neurol 2001; 32: 750-4.
67. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham heart study. Arch Neurol 2006; 63: 246-50.
68. McMurtray AM, Liao A, Haider J, Licht E, Méndez MF. Cognitive performance after lacunar stroke correlates with leukoaraiosis severity. Cerebrovasc Dis 2007; 24: 271-6.
69. Leaper SA, Murray AD, Lemmon HA, Staff RT, Deary IJ, Crawford JR, et al. Neuropsychologic correlates of brain white matter lesions depicted on MR images: 1921 Aberdeen birth cohort. Radiology 2001; 221: 51-5.
70. Van den Heuvel DM, Ten Dam VH, De Craen AJ, Admiraal-Behloul F, Olofsen H, Bollen EL, et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a nondemented elderly population. J Neurol Neurosurg Psychiatry 2006; 77: 149-53.
71. Madureira S, Verdelho A, Ferro J, Basile AM, Chabriat H, Erkinjuntti T, et al. Development of a neuropsychological battery for the leukoaraiosis and disability in the elderly study (LADIS): experience and baseline data. Neuroepidemiology 2006; 27: 101-16.
72. De Leeuw FE, De Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam scan study. J Neurol Neurosurg Psychiatry 2001; 70: 9-14.
73. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National institute of neurological disorders and stroke -Canadian stroke network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220-41.
74. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-22.
75. Schwartz GL, Fornage M, Mosley T, Turner ST. Treatment of leukoaraiosis. Curr Treat Options Cardiovasc Med 2005; 7: 173-7.
76. Hill MD, Bisognano JD. Leukoaraiosis: the brain under pressure -target for treatment? Neurology 2005; 64: 1832-3.
77. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (SYST-EUR) study. Arch Intern Med 2002; 162: 2046-52.
78. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (SYST-EUR) trial. Lancet 1998; 352: 1347-51.
79. Pantoni L, Del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005; 36: 619-24.
80. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian multi-infarct dementia trial. J Neurol Sci 2000; 175: 124-34.
81. Grupo Español de Estudio de Nicardipino en Demencia Vascular. Ensayo clínico experimental, doblemente ciego, aleatorizado, controlado con placebo, del efecto de nicardipino en la función cognitiva en pacientes afectos de demencia vascular. Rev Neurol 1999; 28: 835-45.
82. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2000: CD000269.
83. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci 2007; 257: 264-9.
84. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989; 37: 549-55.
85. Thomas DA, Libon DJ, Ledakis GE. Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. Appl Neuropsychol 2005; 12: 12-8.
86. Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4: 277-93.
87. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69: 448-58.
88. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765-82.
89. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006: CD004746.
90. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-92.
91. Mobius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S172-8.
92. Mobius HJ, Stoffler A. Memantine in vascular dementia. Int Psychogeriatr 2003; 15 (Suppl 1): 207-13.
93. Tanovic A, Alfaro V. Neuroprotección con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular. Rev Neurol 2006; 42: 607-16.
94. Robles-Bayón A. Acción de la memantina sobre la alteración cognitiva del paciente con demencia: reflexiones tras dos años de experiencia en España. Rev Neurol 2006; 42: 288-96.